

Remarks

Claims 1, 4, 5, 11-22, and 41-72 are pending and ready for further action on the merits.

Claims 11-13, 18-22, and 63-72 stand allowed.

Claims 47-60 were withdrawn from consideration by the Examiner.

Claims 43-45 stand rejected under 35 USC § 112, second paragraph, as being indefinite.

Claims 1 and 41 stand rejected under 35 USC § 102(b) as being anticipated by Dobrev et al., Khimicheski Fakultet (1978).

Reconsideration is respectfully requested in light of the following remarks.

Amendments

Claims 43-45 have been amended to clarify the claims. No new matter has been added by way of these amendments.

Claims 43-45 - 35 USC § 112, second paragraph

Claims 43-45 are rejected under 35 USC § 112, second paragraph, for allegedly being indefinite.

Applicants have amended claims 43-45 to remove any method steps in these composition claims.


Withdrawal of the rejection is warranted and respectfully requested.

Claims 1 and 41 - 35 USC § 102(b)

Claims 1 and 41 stand rejected under 35 USC § 102(b) as being anticipated by Dobrev.


Applicants respectfully traverse.

Contrary to the Examiner's statements, Dobrev does not disclose any compounds that fall within the scope of claim 1. Referring to claim 1, the compound of Formula (I) is disclosed.




(I)


The compound of Formula (I) in claim 1 contains an amide substituted with groups R₃ and R₄. The R₄ group has the formula



wherein L is -CH₂-, -O-, -N(H)-, -S-, SO₂-, -CON(H)-, -NHC(O)-, -NHCON(H)-, -NHSO₂-, -SO₂N(H)-, -C(O)-O-, -NHCO₂NH-, -O-CO-,




The N,N-disubstituted amides of formula




in Dobrev include the group -NR₁R₂ where R₁ and R₂ are at the same relative position as R₃ and R₄ in the compound of Formula (I) in claim 1. The -NR₁R₂ group in Dobrev may be pyrrolidino, piperidino, morpholino, N'-methylpyrazolino, and -NMePh and does not include any of the substituted phenyl groups in R₄. Thus, the -NR₁R₂ group in Dobrev does not include any substituent within the scope of R₄ in claim 1. Similar arguments apply to the -NR₁R₂ groups in the compound of Formula (I) and (II) in Dobrev. (Formulas (I) and (II) are shown below).

Further, the N,N-disubstituted amides of the formula above in Dobrev include the group R at the same relative position as the group





in the compound of Formula (I) in claim 1. The R group in Dobrev in the formula above may be -H, -Me, or -Ph. There is no overlap between the R group in the formula above in Dobrev and the group




because R_1 , R_2 , and G_2 together with the carbon to which they are attached can not be selected to be -H, -Me, or -Ph.

With regard to the compounds of Formula (I) and (II) in Dobrev




the groups




(A)

and




(B)

are in the same relative position as the group



in the compound of Formula (I) in claim 1. There is no overlap between either of group (A) and (B) and the group



because neither R_1 , R_2 , nor G_2 can not be selected to be an -OH group or an -NH-C(O)-Ph group.

Thus, Dobrev does not anticipate claim 1 or 41, and withdrawal of the rejection is warranted and respectfully requested.

Withdrawn Claims 47-60

Applicants respectfully request rejoinder of withdrawn claims 47-60.

Fees

This response is being filed within 3 months of the Office Action mailed April 20, 2007, which set a shortened statutory period of three months for a reply. As a result, no extension fee is due.

Should a fee be deemed to be necessary, the Commissioner is hereby authorized to charge any fees required by this action or any future action to Deposit Account No. 50-4060.

Conclusion

With the above amendments and remarks, Applicants believe that all objections and/or rejections have been obviated. Thus, each of the claims remaining in the application is in condition for immediate allowance. A passage of the instant invention to allowance is solicited.

Should the Examiner have any questions relating to the instant application, the Examiner is invited to telephone the undersigned at (336) 841-0300 ext. 159 to discuss any issues.

Respectfully submitted,

Date: May 3, 2007

Samuel B. Rollins
Samuel B. Rollins (Reg. No. 52,180)

TransTech Pharma, Inc.
4170 Mendenhall Oaks Pkwy
High Point, NC 27265
Ph: 336-841-0300 ext. 159
Fax: 336-841-0310